Literature DB >> 12634613

Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.

Jacynthe Gagnon1, Sepideh Shaker, Mélanie Primeau, Annie Hurtubise, Richard L Momparler.   

Abstract

Genes that suppress tumorigenesis can be silenced by epigenetic events, such as aberrant DNA methylation and modification of chromatin structure. Inhibitors of DNA methylase and histone deacetylase (HDAC) can potentially reverse these events. The aim of this study was to determine the in vitro antineoplastic activity of 5-aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylase, in combination with depsipeptide (depsi), an inhibitor of HDAC, on human breast carcinoma cells. We observed a synergistic antineoplastic interaction between 5-AZA-CdR and depsi in their capacity to inhibit colony formation of Hs578T and MCF-7 breast carcinoma cells. In order to understand the molecular mechanism of this interaction, we investigated the effect of these drugs on the activation of the 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 (TIMP3) cancer-related genes, which were reported to be silenced by aberrant methylation in many breast tumor cell lines. 14-3-3sigma was reported to produce G cell cycle arrest following DNA damage. E-cadherin and TIMP3 function as suppressors of tumor metastasis. Semi-quantitative RT-PCR was used to determine the effect of the co-administration of 5-AZA-CdR and depsi on four breast carcinoma cell lines for the reactivation of these genes. We observed a synergistic activation of E-cadherin by the combination in Hs578T, MDA-MB-231 and MDA-MB-435 tumor cells. For 14-3-3sigma, we demonstrated an additive to synergistic activation by the combination for Hs578T and MDA-MB-435 tumor cells, respectively. In the MCF-7 tumor cells, the drug combination produced a synergistic activation of TIMP3. The association between the synergistic antineoplastic activity and the synergistic activation of the target genes in this study suggests that the mechanism of anticancer activity of 5-AZA-CdR, in combination with depsi, is probably related to their enhanced activation of different types of tumor suppressor genes that have been silenced by epigenetic events.(2) Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634613     DOI: 10.1097/00001813-200303000-00002

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  16 in total

1.  Prostaglandin E2 Reverses the Effects of DNA Methyltransferase Inhibitor and TGFB1 on the Conversion of Naive T Cells to iTregs.

Authors:  Mehmet Sahin; Emel Sahin
Journal:  Transfus Med Hemother       Date:  2019-09-19       Impact factor: 3.747

Review 2.  Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.

Authors:  Mahmoud Alhosin; Tanveer Sharif; Marc Mousli; Nelly Etienne-Selloum; Guy Fuhrmann; Valérie B Schini-Kerth; Christian Bronner
Journal:  J Exp Clin Cancer Res       Date:  2011-04-15

Review 3.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

4.  Dynamic changes in E-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer.

Authors:  Kirk Jensen; Aneeta Patel; Victoria Hoperia; Alexander Larin; Andrew Bauer; Vasyl Vasko
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

Review 5.  Cancer epigenetics: a brief review.

Authors:  Shama Virani; Shami Virani; Justin A Colacino; Jung H Kim; Laura S Rozek
Journal:  ILAR J       Date:  2012

6.  Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells.

Authors:  Yajie Zhang; Ruobing Xu; Guiqin Li; Xiaobin Xie; Jie Long; Hongyan Wang
Journal:  Tumour Biol       Date:  2012-07-11

Review 7.  Epigenetic regulation of mmp-9 gene expression.

Authors:  Marilyne Labrie; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2012-11-27       Impact factor: 9.261

8.  Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.

Authors:  Metin Karahoca; Richard L Momparler
Journal:  Clin Epigenetics       Date:  2013-02-01       Impact factor: 6.551

9.  A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.

Authors:  Claudia Arce; Carlos Pérez-Plasencia; Aurora González-Fierro; Erick de la Cruz-Hernández; Alma Revilla-Vázquez; Alma Chávez-Blanco; Catalina Trejo-Becerril; Enrique Pérez-Cárdenas; Lucia Taja-Chayeb; Enrique Bargallo; Patricia Villarreal; Teresa Ramírez; Teresa Vela; Myrna Candelaria; Maria F Camargo; Elizabeth Robles; Alfonso Dueñas-González
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

10.  The role of the CDH1 promoter hypermethylation in the axillary lymph node metastasis and prognosis.

Authors:  Seung Pil Jung; Sangmin Kim; Seok Jin Nam; Insun Kim; Jeoung Won Bae
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.